Physician profile
Eduardo Cepeda
NPI 1285609503
$16,415.88
in general payments reported to CMS, 2019-2025
45 companies · $2,715 in 2025
The $2,715 reported for 2025 was more than what 75% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,721 · 2020: $1,417 · 2021: $2,975 · 2022: $2,075 · 2023: $2,238 · 2024: $2,274 · 2025: $2,715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,128 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,128.08 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,001.98 | 2019-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $2,666.02 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $2,027.83 | 2019-2025 | Tavneos, Otezla, Krystexxa |
| Ucb, INC. | $1,156.00 | 2019-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $699.34 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $646.62 | 2019-2025 | Benlysta, Nucala |
| Pfizer INC. | $637.86 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $563.11 | 2019-2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $542.62 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $486.07 | 2020-2025 | Acthar |
| Lilly USA, LLC | $438.65 | 2019-2024 | Taltz |
| Horizon Therapeutics Plc | $430.35 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $411.06 | 2021-2025 | Lupkynis |
| Celgene Corporation | $338.77 | 2019 | |
| Genentech USA, INC. | $245.40 | 2019-2025 | Actemra, Gazyva, Rituxan |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $237.40 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.78 | 2019-2025 | Cyltezo, Ofev |
| Genzyme Corporation | $195.79 | 2019-2025 | |
| Sobi, INC | $175.29 | 2020-2025 | |
| Abbott Laboratories | $134.47 | 2019-2025 | Proclaim |
| Ani Pharmaceuticals, INC. | $124.24 | 2024-2025 | Purified Cortrophin Gel |
| Octapharma USA, INC. | $120.48 | 2023-2025 | Octagam Immune Globulin (Human), Panzyga |
| Pacira Therapeutics, INC. | $110.30 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $106.45 | 2019-2021 | |
| Radius Health, INC. | $74.52 | 2023 | Tymlos |
| Organon LLC | $69.83 | 2024-2025 | Hadlima |
| Alexion Pharmaceuticals, INC. | $57.36 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $55.97 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $53.07 | 2021-2023 | |
| Hospira, INC. | $50.44 | 2024 | |
| Biocon Biologics INC | $34.23 | 2024-2025 | Hulio |
| Teva Pharmaceuticals USA, INC. | $34.16 | 2023-2024 | Simlandi, Truxima |
| Fresenius Kabi USA, LLC | $32.59 | 2025 | Tyenne |
| Antares Pharma, INC. | $28.23 | 2019 | |
| Daiichi Sankyo INC. | $22.12 | 2019 | |
| Sandoz INC. | $22.12 | 2025 | Hyrimoz |
| Grifols USA, LLC | $21.74 | 2019 | |
| Zimmer Biomet Holdings, INC. | $20.81 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Tersera Therapeutics LLC | $17.14 | 2025 | Quzyttir |
| Kiniksa Pharmaceuticals, LTD. | $16.02 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $15.83 | 2020 | |
| Globus Medical, INC. | $15.12 | 2025 | Senza |
| Shionogi INC | $14.83 | 2019 | |
| Gilead Sciences, INC. | $14.77 | 2020 | |
| Medtronic, INC. | $14.10 | 2025 | Synchromedii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Cepeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.